Paulina Delgado-Gonzalez

Dr. Paulina Delgado-Gonzalez

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Life
Verified
Journal Article
Open access
PDF file
JRJorge A Roacho-Pérez
Jorge A Roacho-Pérez
EGElsa Garza-Treviño
Elsa Garza-Treviño
NMNIDIA KARINA MONCADA-SAUCEDO
NIDIA KARINA MONCADA-SAUCEDO
PCPablo Alfonso Carriquiry-Chequer
Pablo Alfonso Carriquiry-Chequer
LVLaura Elizabeth Valencia-Gomez
Laura Elizabeth Valencia-Gomez
JIJose Francisco Islas
Jose Francisco Islas
Cardiovascular diseases are a leading cause of death worldwide. Current treatments directed at heart repair have several disadvantages, such as a lack of donors for heart transplantation or non-bioactive inert materials for replacing damaged tissue. Because of the natural lack of regeneration of cardiomyocytes, new treatment strategies involve stimulating heart tissue regeneration. The basic three elements of cardiac tissue engineering (cells, growth factors, and scaffolds) are described in this review, with a highlight on the role of artificial scaffolds. Scaffolds for cardiac tissue engineering are tridimensional porous structures that imitate the extracellular heart matrix, with the ability to promote cell adhesion, migration, differentiation, and proliferation. In the heart, there is an important requirement to provide scaffold cellular attachment, but scaffolds also need to permit mechanical contractility and electrical conductivity. For researchers working in cardiac tissue engineering, there is an important need to choose an adequate artificial scaffold biofabrication technique, as well as the ideal biocompatible biodegradable biomaterial for scaffold construction. Finally, there are many suitable options for researchers to obtain scaffolds that promote cell–electrical interactions and tissue repair, reaching the goal of cardiac tissue engineering.

Verified
Journal Article
Open access
PDF file
Antonio Rojas-MurilloAntonio Rojas-Murillo
Antonio Rojas-Murillo
MSMario Simental-Mendía
Mario Simental-Mendía
NMNIDIA KARINA MONCADA-SAUCEDO
NIDIA KARINA MONCADA-SAUCEDO
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
JIJose Francisco Islas
Jose Francisco Islas
EGElsa Garza-Treviño
Elsa Garza-Treviño
Articular cartilage is a highly organized tissue that provides remarkable load-bearing and low friction properties, allowing for smooth movement of diarthrodial joints; however, due to the avascular, aneural, and non-lymphatic characteristics of cartilage, joint cartilage has self-regeneration and repair limitations. Cartilage tissue engineering is a promising alternative for chondral defect repair. It proposes models that mimic natural tissue structure through the use of cells, scaffolds, and signaling factors to repair, replace, maintain, or improve the specific function of the tissue. In chondral tissue engineering, fibrin is a biocompatible biomaterial suitable for cell growth and differentiation with adequate properties to regenerate damaged cartilage. Additionally, its mechanical, biological, and physical properties can be enhanced by combining it with other materials or biological components. This review addresses the biological, physical, and mechanical properties of fibrin as a biomaterial for cartilage tissue engineering and as an element to enhance the regeneration or repair of chondral lesions.

1 July 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
EGElsa Garza-Treviño
Elsa Garza-Treviño
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
CSCarlos I. Valencia Salgado
Carlos I. Valencia Salgado
AGAlejandra Martinez Garza
Alejandra Martinez Garza
Colorectal cancer (CRC) is one type of tumor with the highest frequency and mortality worldwide. Although current treatments increase patient survival, it is important to detect CRC in early stages; however, most CRC, despite responding favorably to treatment, develop resistance and present recurrence, a situation that will inevitably lead to death. In recent years, it has been shown that the main reason for drug resistance is the presence of colon cancer stem cells (CSC). Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME), contributing to the formation of vessels and promoting metastasis; however, they have not been considered very important as a therapeutic target in cancer. In this review, we highlight the contribution of pericytes and cancer stem cells to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss therapies targeting pericytes and cancer stem cells in CRC.

28 September 2023 in Life
Verified
Journal Article
Open access
PDF file
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
EGElsa Garza-Treviño
Elsa Garza-Treviño
DKDavid A. de la Garza Kalife
David A. de la Garza Kalife
AQAdriana G Quiroz-Reyes
Adriana G Quiroz-Reyes
EHEsther Alhelí Hernández-Tobías
Esther Alhelí Hernández-Tobías
Colorectal cancer (CRC) is one of the most common causes of death and the third most diagnosed cancer worldwide. The tumor microenvironment and cancer stem cells participate in colorectal tumor progression and can dictate malignancy. Nutrition status affects treatment response and the progression or recurrence of the tumor. This review summarizes the main bioactive compounds against the molecular pathways related to colorectal carcinogenesis. Moreover, we focus on the compounds with chemopreventive properties, mainly polyphenols and carotenoids, which are highly studied dietary bioactive compounds present in major types of food, like vegetables, fruits, and seeds. Their proprieties are antioxidant and gut microbiota modulation, important in the intestine because they decrease reactive oxygen species and inflammation, both principal causes of cancer. These compounds can promote apoptosis and inhibit cell growth, proliferation, and migration. Combined with oncologic treatment, a sensitization to first-line colorectal chemotherapy schemes, such as FOLFOX and FOLFIRI, is observed, making them an attractive and natural support in the oncologic treatment of CRC.

5 November 2021 in Life
Verified
Journal Article
Open access
PDF file
JRJorge A Roacho-Pérez
Jorge A Roacho-Pérez
EGElsa Garza-Treviño
Elsa Garza-Treviño
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
ZGZuca G-Buentello
Zuca G-Buentello
JDJuan Luis Delgado
Juan Luis Delgado
JIJose Francisco Islas
Jose Francisco Islas
Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which produce several side effects. This review focuses on the use of targeted nanoparticles, such as metallic nanoparticles, polymeric nanoparticles, liposomes, micelles, and carbon nanotubes as an alternative to standard treatment for pancreatic cancer. The principal objective of nanoparticles is reduction of the side effects that conventional treatments produce, mostly because of their non-specificity. Several molecular markers of pancreatic cancer cells have been studied to target nanoparticles and improve current treatment. Therefore, properly functionalized nanoparticles with specific aptamers or antibodies can be used to recognize pancreatic cancer cells. Once cancer is recognized, these nanoparticles can attack the tumor by drug delivery, gene therapy, or hyperthermia.

Verified
Journal Article
Open access
PDF file
EGElsa Garza-Treviño
Elsa Garza-Treviño
AQAdriana G Quiroz-Reyes
Adriana G Quiroz-Reyes
Antonio Rojas-MurilloAntonio Rojas-Murillo
Antonio Rojas-Murillo
DKDavid A de la Garza Kalife
David A de la Garza Kalife
PDPaulina Delgado-Gonzalez
Paulina Delgado-Gonzalez
CVCarlos Alberto Gonzalez Villarreal
Carlos Alberto Gonzalez Villarreal
Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development. Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs. We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.